Infection, Human Immunodeficiency Virus
Showing 1 - 25 of 113
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK744, GSK744 LA, TMC278 LA)
Active, not recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK744
- +4 more
-
Birmingham, Alabama
- +49 more
Dec 26, 2022
Infection, Human Immunodeficiency Virus, HIV, Arthralgia Trial in Orel, St. Petersburg, Madrid (DTG 50 mg /ABC 600 mg /3TC 300
Completed
- Infection, Human Immunodeficiency Virus
- +2 more
- DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
-
Orel, Russian Federation
- +2 more
Sep 9, 2022
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil
Active, not recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Dolutegravir (DTG)
- +2 more
-
Phoenix, Arizona
- +89 more
Jun 27, 2022
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK1349572, Raltegravir, GSK1349572 Placebo)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK1349572
- +3 more
-
Birmingham, Alabama
- +180 more
Mar 14, 2022
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir)
Active, not recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Dolutegravir/abacavir/lamivudine FDC
- +3 more
-
Phoenix, Arizona
- +88 more
Feb 8, 2022
(APR): Multi-sponsor Registry to Detect Any Major Teratogenic
Recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Any Antiretroviral Therapy
-
Wilmington, North CarolinaGSK Investigational Site
Oct 4, 2021
Infection, Human Immunodeficiency Virus, HIV Trial in Cambridge (GSK3640254, Placebo)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK3640254
- Placebo
-
Cambridge, United KingdomGSK Investigational Site
May 28, 2021
Infection, Human Immunodeficiency Virus Trial (cabotegravir, CAB)
Available
- Infection, Human Immunodeficiency Virus
- cabotegravir, CAB
- (no location specified)
May 19, 2021
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (DTG 50 mg, EFV 600 mg)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- DTG 50 mg
- EFV 600 mg
-
Ciudad de Buenos Aires, Buenos Aires, Argentina
- +27 more
Dec 18, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Baltimore (GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK2838232 100 mg tablet
- +3 more
-
Baltimore, MarylandGSK Investigational Site
Oct 6, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Gent (Blood sampling)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Blood sampling
-
Gent, BelgiumGSK Investigational Site
Sep 25, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
-
Phoenix, Arizona
- +73 more
Sep 28, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Cambridge (Cabotegravir, Rifabutin)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
-
Cambridge, United KingdomGSK Investigational Site
Aug 27, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Lakewood, Minneapolis (GSK1265744 30 mg)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK1265744 30 mg
-
Lakewood, Colorado
- +1 more
Aug 27, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Baltimore, Pittsburgh (Cabotegravir tablet 30 mg once daily for 28 days.,
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Cabotegravir tablet 30 mg once daily for 28 days.
- Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
-
Baltimore, Maryland
- +1 more
Jun 2, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Buffalo (GSK2248761 formulation 1, GSK2248761 reference formulation,
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK2248761 formulation 1
- +3 more
-
Buffalo, New YorkGSK Investigational Site
Mar 25, 2020
Human Immunodeficiency Virus-1 Infection in HIV-1 Uninfected
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Risk reduction counseling
- +2 more
-
Guangzhou, Guangdong, China
- +8 more
Mar 10, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Canada, United States (GSK2838232, Cobicistat)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
-
Birmingham, Alabama
- +13 more
Mar 2, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Canada, United States (GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK1265744 10 mg
- +6 more
-
Birmingham, Alabama
- +47 more
Jan 21, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Berlin (BMS-955176, Placebo matching with BMS-955176, Atazanavir)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- BMS-955176
- +5 more
-
Berlin, GermanyGSK Investigational Site
Nov 4, 2019
Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus Trial in Minneapolis (GSK1349572)
Completed
- Healthy Subjects
- +3 more
-
Minneapolis, MinnesotaGSK Investigational Site
Jul 29, 2019
Infection, Human Immunodeficiency Virus, HIV Trial in Overland Park (DTG, RPV, DTG/RPV FDC)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- DTG
- +2 more
-
Overland Park, KansasGSK Investigational Site
Jul 11, 2019
Infection, Human Immunodeficiency Virus, HIV Trial in Austin (GSK1349572)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
-
Austin, TexasGSK Investigational Site
Jun 20, 2019
Infection, Human Immunodeficiency Virus Trial in Overland Park (Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC
Completed
- Infection, Human Immunodeficiency Virus
- Dolutegravir
- +3 more
-
Overland Park, KansasGSK Investigational Site
Oct 10, 2018
Infection, Human Immunodeficiency Virus, HIV Trial in Fargo (YASMIN, GSK2248761, Placebo)
Terminated
- Infection, Human Immunodeficiency Virus
- HIV Infections
- YASMIN
- +2 more
-
Fargo, North DakotaGSK Investigational Site
Feb 18, 2019